A novel molecule with superior performance is tirzepatide, a GLP-1 and GIP (Gastric Inhibitory Peptide) receptor agonist and recent results from the SURPASS and SURMOUNT programs are briefly described
Outcomes Our primary outcome was a composite outcome encompassing five major clinical events: all-cause hospitalization, all-cause mortality, major adverse cardiovascular events (MACEs), major adverse kidney events (MAKEs), major adverse liver outcomes (MALO), and hepatocellular carcinoma (HCC)
For those concerned about side effects Tirzepatide has the best overall tolerability profile in clinical trials, with the lowest discontinuation rates
UnitedHealthcare: Includes GLP-1 medications in many plans, managed by Klinic
Placing your vials in a sealed container with a desiccant inside the freezer helps absorb any ambient moisture, providing an additional layer of protection against accidental hydrolysis
Recent trials have shown: Up to 20% body weight reduction with weekly GLP-1 agonists (Wilding et al., NEJM) Improvements in HbA1c, fasting glucose, and cardiovascular outcomes (Marso et al., NEJM) This drug class is now widely used for: Obesity (with or without diabetes) Type 2 diabetes PCOS-related insulin resistance Metabolic syndrome Common Side Effects and Patient Concerns Despite their benefits, GLP-1 agonists are not without risks or drawbacks
